Preventive effects with teriparatide or alendronate on the progression of vertebral collapse

Preventive effects with teriparatide or alendronate on the progression of vertebral collapse - T-WRAP (Teriparatide for new vertebral fractures to wedge deformity prevention study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013014

Enrollment

200

Registered

2014-02-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Teriparatide Alendronate

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women with fragility vertebral compression fracture

Exclusion criteria

Exclusion criteria: 1. Patients with vertebral compression fractures which is not clear the time of injury. 2. Patients received teriparatide or denosumab within 6 months prior to the study. 3. Patients with contraindications of teriparatide or alendronate. 4. Patients with severe renal dysfunction, severe liver dysfunction, or severe heart disease. 5. Inappropriate patients to participate the study judged by primary physician.

Design outcomes

Primary

Measure	Time frame
Progression of vertebral collapse fracture	—

Secondary

Measure	Time frame
Pain, QOL, Bone turnover markers, Bone mineral density	—

Countries

Japan

Contacts

Public ContactKazumasa Tanzawa

EPS corporation CEO Office

tanzawa517@eps.co.jp03-5684-7797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026